RE:old enough to remember You're so far out to lunch with that post that I'm almost emarassed for you.
Early buyout upon the formation of Vantive post 90 was ( and still is ) only a possibility !
Failing that, top line release becomes another key date to watch in terms of long overdue shareholder ROI.
Great insights gained today, but I'm not inclined to share my thoughts here with the usual gaggle of yahoos milling about.
Stick with your usual grumblings. Pick from your favourite topics. Let me help you : a slow enrolment month of May, 18 -24 months until FDA's final final ruling after last patient enrolled, maxing out at only 23 sites with 42 patients left ti enroll, technical glitches at AGM . Be sure Ignore the magnitude of the opportunity in front of you and dissuade all comers with your incessant whining.
I'll stick with the things I like about Spectral such as:
strengthening bench, exceeding expectations, lack of market alternatives, importance of diagnostics combined with treatments ( precision medicine) , exclusivity guarantee, key distribution partnerships with financial support, obscene EBITDA multiples for similar/successful companies , mounting real world evidence beyond just ESS, the inevitable denouement moment that will arrive
I remain Long and strong ( hopeful and patient)
MM